Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections

被引:674
作者
Hurdle, Julian G. [1 ,2 ]
O'Neill, Alex J. [3 ,4 ]
Chopra, Ian [3 ,4 ]
Lee, Richard E. [2 ]
机构
[1] Univ Texas Arlington, Dept Biol, Arlington, TX 76019 USA
[2] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA
[3] Univ Leeds, Antimicrobial Res Ctr, Leeds LS2 9JT, W Yorkshire, England
[4] Univ Leeds, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England
基金
美国国家卫生研究院;
关键词
IN-VITRO ACTIVITY; PSEUDOMONAS-AERUGINOSA BIOFILMS; CATIONIC ANTIMICROBIAL PEPTIDES; CYSTIC-FIBROSIS LUNG; PROTON MOTIVE FORCE; STAPHYLOCOCCUS-AUREUS; MYCOBACTERIUM-TUBERCULOSIS; CHLAMYDIA-TRACHOMATIS; ESCHERICHIA-COLI; NITROIMIDAZOPYRAN PA-824;
D O I
10.1038/nrmicro2474
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
Persistent infections involving slow-growing or non-growing bacteria are hard to treat with antibiotics that target biosynthetic processes in growing cells. Consequently, there is a need for antimicrobials that can treat infections containing dormant bacteria. In this Review, we discuss the emerging concept that disrupting the bacterial membrane bilayer or proteins that are integral to membrane function (including membrane potential and energy metabolism) in dormant bacteria is a strategy for treating persistent infections. The clinical applicability of these approaches is exemplified by the efficacy of lipoglycopeptides that damage bacterial membranes and of the diarylquinoline TMC207, which inhibits membrane-bound ATP synthase. Despite some drawbacks, membrane-active agents form an important new means of eradicating recalcitrant, non-growing bacteria.
引用
收藏
页码:62 / 75
页数:14
相关论文
共 166 条
[1]
The chlamydial developmental cycle [J].
AbdelRahman, YM ;
Belland, RJ .
FEMS MICROBIOLOGY REVIEWS, 2005, 29 (05) :949-959
[2]
Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine [J].
Adams, LB ;
Sinha, I ;
Franzblau, SG ;
Krahenbuhl, JL ;
Mehta, RT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1638-1643
[3]
Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues [J].
Allen, NE ;
LeTourneau, DL ;
Hobbs, JN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :66-71
[4]
Mechanism of action of oritavancin and related glycopeptide antibiotics [J].
Allen, NE ;
Nicas, TI .
FEMS MICROBIOLOGY REVIEWS, 2003, 26 (05) :511-532
[5]
Responses of Pseudomonas aeruginosa to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration [J].
Alvarez-Ortega, Carolina ;
Harwood, Caroline S. .
MOLECULAR MICROBIOLOGY, 2007, 65 (01) :153-165
[6]
Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! [J].
Amaral, Leonard ;
Boeree, Martin J. ;
Gillespie, Stephen H. ;
Udwadia, Zarir F. ;
van Soolingen, Dick .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (06) :524-526
[7]
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].
Andries, K ;
Verhasselt, P ;
Guillemont, J ;
Göhlmann, HWH ;
Neefs, JM ;
Winkler, H ;
Van Gestel, J ;
Timmerman, P ;
Zhu, M ;
Lee, E ;
Williams, P ;
de Chaffoy, D ;
Huitric, E ;
Hoffner, S ;
Cambau, E ;
Truffot-Pernot, C ;
Lounis, N ;
Jarlier, V .
SCIENCE, 2005, 307 (5707) :223-227
[8]
Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci [J].
Arthur, M ;
Depardieu, F ;
Reynolds, P ;
Courvalin, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1875-1880
[9]
Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564
[10]
Respiratory ATP synthesis: the new generation of mycobacterial drug targets? [J].
Bald, Dirk ;
Koul, Anil .
FEMS MICROBIOLOGY LETTERS, 2010, 308 (01) :1-7